Written and fact-checked to our published editorial standards.Last updated 2026-08-21. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.
Direct answer
What you need to know
Evidence strength: Strong
Tirzepatide has no approved tablet, so the cheapest route that exists for semaglutide does not exist here. Every FDA-approved tirzepatide product is a weekly injection, and the published self-pay price depends on the device — a vial and a pen of the same medication are not priced alike. Compounded tirzepatide is advertised lower, by markedly fewer providers than offer compounded semaglutide, and with litigation attached.
Key takeaways
No oral form exists. A “tirzepatide pill” is not a cheaper option, it is not a product.
The device changes the price for the same drug, so ask which one you are being prescribed.
3 providers in our directory name compounded tirzepatide, against 6 for semaglutide.
Eli Lilly filed suit in April 2025 over compounded tirzepatide marketing; one case was dismissed.
Important limitation: These are published list prices, not quotes, and the compounded end of this molecule is the part of the market most likely to change. We report what providers publish, and we have not used any of them.
Next action: If your question is which way of paying is cheapest rather than which molecule, that is the route-by-route comparison. For the molecule that does have a tablet, see what semaglutide costs.
General education, not medical advice. Prices in this category move fast — confirm before you buy.
The missing tablet is the whole story
For semaglutide, the cheapest published route to an approved product is a daily tablet at $149 a month. Tirzepatide has no equivalent. Zepbound and Mounjaro are weekly injections and nothing else, so the floor for this molecule is set by injection pricing.
That single fact explains most of what people notice when they compare the two: not that tirzepatide is a premium drug, but that the cheap format is unavailable. It is also why the comparison people usually want — “which is cheaper” — has a different answer depending on whether you can take a tablet at all.
The second thing that moves the price is the device. The same medication in a vial and in an auto-injector pen carry different published self-pay figures, and on Medicare they can carry different coverage answers. That is covered in how price varies by route and device.
The same three rungs as the semaglutide chart, on the same scale. The top one is empty: there is no approved tirzepatide tablet to price, which is why this molecule has no cheap format to fall back on.Manufacturer self-pay pages and provider pricing pages, verified 2026-08-11.
Every provider in our directory whose own published wording names tirzepatide, grouped by whether the medication is FDA-approved or compounded, then ordered by the lowest published monthly figure. Ordering by price is not a judgement of quality — we have not used any of these services. Each row carries the date we last read that provider’s terms.
Provider and option
Monthlyfee + medication
What that figure is made of
Checked
FDA-approved tirzepatide
Noom MedTelehealth-only plan plus a brand-name medication
at least $39/mo
Plan: $39 — Access to brand-name medications advertised from $39/month, before whatever the medication costs under the member's own insurance.Medication: not published — Brand-name Wegovy or Zepbound is billed separately; Noom does not publish a price for it.
Membership: $74 — $25/month for the first two months on a 12-month plan, then $74/month for the remainder — a promotional rate WeightWatchers dates to an offer ending 13 August 2026.Medication: not published — Not included in the membership; cost depends on pharmacy and insurance, and WeightWatchers does not publish a figure.
Membership: $20 — $19.99/month membership with the first month free, rounded up to $20 here.Visit: $129 — $129 per visit without insurance; around $30 per visit for insured patients.Medication: not published — Billed separately by the pharmacy. PlushCare does not publish a medication price, because it does not set one.
2026-08-11
CalibrateThe Metabolic Reset, medication billed to insurance
at least $199/mo
Programme fee: $199 — $199/month with a three-month minimum, which Calibrate states brings the initial commitment to $597.Medication: not published — Calibrate bills medication and labs to the member's own insurance and publishes no cash price. It states GLP-1 copays for most commercially insured members are typically $25/month or less once any deductible is met.
2026-08-11
Ro (Body)Annual-prepay membership plus new-patient brand pricing
$223/mo
Membership: $74 — As low as $74/month on an annual prepay; $149/month month-to-month, after a $39 first month.Medication: $149 — New-patient offers from $149/month for first-dose Wegovy or Foundayo tablets.
2026-08-11
Hims & HersClinical membership plus a brand-name medication
$298/mo
Membership: $149 — $39 first month, $149/month thereafter, billed separately from medication.Medication: $149 — From $149–$399/month depending on product and dose.
2026-07-26
FoundCoaching membership plus brand-name Zepbound vials
$749/mo
Membership: $99 — Coaching and community membership roughly $99–$149/month.Medication: $650 — Found lists Wegovy and Zepbound from $650/month on direct pay, and Ozempic and Mounjaro at around $1,100/month.
2026-08-11
Compounded tirzepatide
Mochi HealthMembership plus a 4-week supply of compounded tirzepatide
$169/mo
Membership: $79 — $79/month standard membership; an introductory $39 first month in eligible states.Medication: $90 — Compounded tirzepatide advertised from $90/month, presented as a reduction from $199. Read 2026-08-21.
Willow Health does not publish a stable price list, so there is nothing here to total. A provider that will not tell you the price before you sign up is itself a finding.
2026-07-26
There is no generic tirzepatide, and there is a generic GLP-1
“Generic tirzepatide” is one of the most common things people search for at this point, and it does not exist. We checked rather than assumed: on 2026-08-21 the FDA’s own label data showed tirzepatide approved under 2 applications — NDA215866 and NDA217806 — and no abbreviated application at all. An abbreviated application is the pathway a generic goes through. No ANDA, no generic.
This matters more than a definitional point, because the gap gets filled by the wrong thing. A compounded vial is not a generic and the two are not related: a generic is an approved product proven equivalent to the original, and a compounded preparation has been reviewed by nobody. Anything sold to you as “generic tirzepatide” is one of those two things mislabelled.
The part almost nobody says out loud is that a generic GLP-1 does exist — just not this molecule. liraglutide has 8 approved generics (Teva, Biocon, Lupin, Hikma among the holders), sold as Victoza and Saxenda, and exenatide has 1 approved generic, sold as Byetta. Those are older drugs with smaller published weight-loss results, so this is a real trade rather than a loophole — but if the word “generic” is what brought you here, that is where the generics are. What liraglutide is sits with the rest of the drug reference.
Who each of these is for
If you have insurance that covers Zepbound. That beats every cash figure here, and it is the first question the route comparison asks.
If you are paying cash for the approved product. Ask which device the prescription specifies before you compare prices, because the answer changes the number.
If you are considering compounded tirzepatide. Fewer providers offer it than offer compounded semaglutide, and this is the molecule at the centre of the April 2025 litigation. The dated entries, including the case that was dismissed, are in our log of provider changes. What compounding means, and what it does not, is on the compounded guide.
3 providers we could not file here
These advertise a GLP-1 at a price without naming the molecule. They may supply tirzepatide. They are not in the table above because putting them there would be a guess presented as a comparison.
Tirzepatide is not priced higher because it is treated as premium. It is priced higher because the cheap format does not exist.
Common questions
Is there a generic tirzepatide?
No. Checked against the FDA's own label data on 2026-08-21, tirzepatide is approved under 2 applications — NDA215866 and NDA217806 — and no abbreviated application at all, which is the pathway an approved generic goes through. Compounded tirzepatide is not a generic and is not an approved product; the two are unrelated. A generic GLP-1 does exist, but it is a different molecule: liraglutide, which has 8; exenatide, which has 1.
What is the cheapest way to get tirzepatide?
Every approved tirzepatide product is an injection, and the published self-pay price varies by device — a vial is cheaper than a pen for the same drug. Compounded tirzepatide is advertised lower by a small number of telehealth providers, but fewer offer it than offer compounded semaglutide, and the compounded end of this molecule carries litigation the semaglutide end does not.
Is there a tirzepatide pill?
No. Tirzepatide has no FDA-approved oral form. If you want a GLP-1 you swallow, the approved options are oral semaglutide — Rybelsus or Wegovy tablets — or orforglipron, sold as Foundayo. That is a different molecule, not a cheaper tirzepatide.
Why is tirzepatide often more expensive than semaglutide?
Partly because there is no tablet to fall back on. The cheapest published route to an approved semaglutide product is a daily tablet; for tirzepatide the floor is set by injection pricing, and the device you are prescribed changes it.
Is compounded tirzepatide legal?
It is sold, and Eli Lilly filed federal lawsuits in April 2025 against several telehealth companies over the marketing of compounded tirzepatide. One case in our directory was dismissed in September 2025. We record what is on the public record rather than characterising it — the dated entries are in our log of provider changes.
How these figures are kept honest
Every figure comes from the provider’s own published page or the manufacturer’s, carries the date we read it, and is re-checked on a schedule. Costs were last verified 2026-08-11; the last full directory sweep ran 2026-08-11 and the next is due 2026-09-10. What a provider must satisfy to appear at all is set out in the listing standard.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
Zepbound coverage and savingsEli Lilly and CompanySupports: Zepbound self-pay pricing by device and dose. Verified 2026-07-25.
Drug label data, queried by generic name for application numbersopenFDA, U.S. Food & Drug AdministrationSupports: The application numbers behind every approved GLP-1, read to establish which molecules have an approved generic and which do not. Counted 2026-08-21.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.